Dipeptidyl-peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists, two classes of medication for the treatment of type 2 diabetes, were assessed in an experimental model of myocardial ischemia in rats [62]. This evidence concerns the gene DPP4 and myocardial ischemia.